Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

ClinicalTrials.gov ID: NCT00628095

Public ClinicalTrials.gov record NCT00628095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF CE-224,535, AN ANTAGONIST OF THE P2X7 RECEPTOR, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN SUBJECTS WHO ARE INADEQUATELY CONTROLLED ON METHOTREXATE

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis

Study identification

NCT ID
NCT00628095
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
100 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 6, 2008
Primary completion
Feb 3, 2009
Completion
Feb 3, 2009
Last update posted
Apr 3, 2022

2008 – 2009

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
Arizona Arthritis & Rheumatology Associates, P.C. Mesa Arizona 85202
Omega Research Consultants LLC DeBary Florida 32713
Florida Arthritis Center Lake Mary Florida 32746
Tampa Medical Group, PA Tampa Florida 33614
American Health Network Avon Indiana 46123
Best Clinical Trials, LLC (Administrative Only) New Orleans Louisiana 70115
George Stanley Walker, MD New Orleans Louisiana 70115
Majid Abdul Jawad, MD New Orleans Louisiana 70115
The Arthritis and Osteoporosis Center of Maryland Frederick Maryland 21702
University Physicians Columbia Missouri 65203
University of Missouri-Columbia Columbia Missouri 65212
Arthritis Center of Reno Reno Nevada 89502
New Horizons Clinical Research Cincinnati Ohio 45242
Arthritis Northwest Spokane Washington 99204-2336

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00628095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2022 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00628095 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →